Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors

@article{ElRayes2004PhaseIS,
  title={Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors},
  author={Basil F. El-Rayes and Dina Essam Eldeen Ibrahim and Anthony Frank Shields and Patricia M. LoRusso and Mark M. Zalupski and Philip Agop Philip},
  journal={Investigational New Drugs},
  year={2004},
  volume={23},
  pages={57-62}
}
Introduction: The purpose of this study was to determine the recommended phase II dose (RPTD) of the combination of cyclophosphamide and liposomal doxorubicin (Doxil). Patients and methods: Eligibility criteria included: a diagnosis of non-hematologic cancer with no conventional effective therapy, normal renal, liver and bone marrow function, and ECOG performance status of 0-2. Both drugs were administered intravenously on day 1 of a 21-day cycle. The following doses (mg/m2) of Doxil and… CONTINUE READING